The National Institute of Health and Care Excellence (NICE) has approved the use of pemigatinib in adults with a rare type of bile duct cancer that has continued to advance or spread after initial chemotherapy.
An existing combination of chemotherapy could be used to provide a new option for biliary tract cancer patients.
Patients who take capecitabine after surgery for bile duct cancer live for almost a year and a half longer than those not given the drug.
A new treatment increases survival to almost 70 per cent for children whose acute lymphoblastic leukaemia (ALL) returns.
Finding new treatments for rare and hard-to-treat cancers is one of our greatest challenges. The best way of testing out…